FELICETTI, CRISTIANO
 Distribuzione geografica
Continente #
NA - Nord America 131
AS - Asia 66
EU - Europa 59
SA - Sud America 13
AF - Africa 7
Totale 276
Nazione #
US - Stati Uniti d'America 128
SG - Singapore 29
CN - Cina 18
IT - Italia 14
DE - Germania 12
RU - Federazione Russa 11
BR - Brasile 10
HK - Hong Kong 8
FI - Finlandia 5
IE - Irlanda 5
CI - Costa d'Avorio 4
FR - Francia 4
VN - Vietnam 4
GB - Regno Unito 3
HN - Honduras 2
JP - Giappone 2
SE - Svezia 2
AR - Argentina 1
AZ - Azerbaigian 1
BH - Bahrain 1
BO - Bolivia 1
CA - Canada 1
CL - Cile 1
EG - Egitto 1
GR - Grecia 1
IN - India 1
KE - Kenya 1
NL - Olanda 1
PL - Polonia 1
SA - Arabia Saudita 1
TW - Taiwan 1
ZA - Sudafrica 1
Totale 276
Città #
Ashburn 34
Singapore 21
Los Angeles 15
Boardman 12
Munich 11
Hong Kong 8
Dallas 7
Santa Clara 6
The Dalles 6
Dublin 5
New York 5
Turku 5
Abidjan 4
Rome 4
Hefei 3
Ho Chi Minh City 3
Moscow 3
Turin 3
Beijing 2
Denver 2
El Progreso 2
Stockholm 2
São Paulo 2
Tokyo 2
Urbisaglia 2
Washington 2
Amsterdam 1
Ancona 1
Atlanta 1
Baku 1
Boston 1
Brooklyn 1
Buffalo 1
Cairo 1
Can Tho 1
Changping 1
City of London 1
Cochrane 1
Columbus 1
Cosmópolis 1
Fermignano 1
Frankfurt am Main 1
Gainesville 1
Goiânia 1
Guangzhou 1
Hamad Town 1
Ipaumirim 1
Johannesburg 1
La Paz 1
Laredo 1
Libertad 1
Manhuaçu 1
Mauá 1
Medina 1
Miami 1
Montes Claros 1
Montreal 1
Nairobi 1
New Delhi 1
Orem 1
Phoenix 1
Poplar 1
Quanzhou 1
Rancho Palos Verdes 1
Roubaix 1
Salt Lake City 1
San Francisco 1
Santa Maria 1
São Pedro 1
Taipei 1
Virginia Beach 1
Warsaw 1
Wuhan 1
Totale 218
Nome #
Hemoglobin and Neutrophil Count as Prognostic Factors in Cholangiocarcinoma Patients in 2nd Line Treatment Setting: Results from a Small Monocentric Retrospective Study 85
Current Evidence and Future Perspectives about the Role of PARP Inhibitors in the Treatment of Thoracic Cancers 68
Primary versus secondary antiemetic prophylaxis with NK1 receptor antagonists in patients affected by gastrointestinal malignancies and treated with a doublet or triplet combination regimen including oxaliplatin and/or irinotecan plus fluoropyrimidines: A propensity score matched analysis 68
The Landscape of ALK-Rearranged Non-Small Cell Lung Cancer: A Comprehensive Review of Clinicopathologic, Genomic Characteristics, and Therapeutic Perspectives 68
Totale 289
Categoria #
all - tutte 1.716
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 1.716


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2022/202314 0 0 0 0 0 0 0 0 0 5 7 2
2023/202442 4 2 5 5 7 9 1 0 0 3 0 6
2024/202588 11 6 3 3 5 4 6 1 11 7 19 12
2025/2026145 24 18 12 35 40 16 0 0 0 0 0 0
Totale 289